{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T09:31:17Z","timestamp":1762507877019,"version":"build-2065373602"},"reference-count":43,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2019,10,25]],"date-time":"2019-10-25T00:00:00Z","timestamp":1571961600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomolecules"],"abstract":"<jats:p>Immunoadsorption and subsequent administration of intravenous immunoglobulin (IVIG) have shown beneficial effects on cardiac function and symptoms in patients with dilated cardiomyopathy. Biomarkers play an emerging role in disease monitoring and outcome prediction of heart failure (HF) patients. We aimed to analyze cardiac biomarkers as predictor for improvement of left ventricular (LV) function after immunoadsorption treatment in dilated cardiomyopathy (DCM). Thirty-one patients with dilated cardiomyopathy on optimized HF pharmacotherapy received a single cycle of immunoadsorption for five days followed by IVIG administration. Left ventricular ejection fraction (LVEF) and heart failure biomarkers (hs troponin T, hs troponin I, NT-proBNP and sST2) were evaluated before treatment, after the last cycle of immunoadsorption and during a median follow-up of 30.5 months. We correlated HF biomarkers before immunoadsorption and acute changes of HF biomarkers by immunoadsorption with LV improvement during the long-term follow-up. LV function improved significantly after immunoadsorption from 28.0 to 42.0% during the long-term follow-up (p &lt; 0.0001). Evaluation of biomarker levels showed a significant decrease for hs troponin I (from 9.2 to 5.5 ng\/L, p &lt; 0.05) and NT-proBNP (from 789.6 to 281.2 pg\/mL, p &lt; 0.005). Correlation of biomarker levels before immunoadsorption and LVEF at the long-term follow-up show good results for hs troponin T (r = \u22120.40, r2 = 0.16, p &lt; 0.05), hs troponin I (r = \u22120.41, r2 = 0.17, p &lt; 0.05) and sST2 (r = \u22120.46, r2 = 0.19, p &lt; 0.05). Correlation of biomarker levels before immunoadsorption and the individual increase in LV function was significant for hs troponin T (r = \u22120.52, r2 = 0.27, p &lt; 0.005) and hs troponin I (r = \u22120.53, r2 = 0.29, p &lt; 0.005). To imply a tool for monitoring outcome immediately after immunoadsorption treatment, we investigated the correlation of acute changes of biomarker levels by immunoadsorption treatment and individual increase in LV function. A drop in hs troponin T (r = \u22120.41, r2 = 0.17, p &lt; 0.05) and hs troponin I (r = \u22120.53, r2 = 0.28, p &lt; 0.005) levels demonstrate a good correlation to improvement in LVEF during the long-term follow-up. Conclusion: Hs troponin T and I levels correlate with LV function improvement during long-term follow-up. Acute decrease of troponins by immunoadsorption treatment is paralleled by individual improvement of LVEF at the long-term follow-up. Thus, troponins could serve as a monitoring tool for the improvement of LV function after immunoadsorption treatment in dilated cardiomyopathy.<\/jats:p>","DOI":"10.3390\/biom9110654","type":"journal-article","created":{"date-parts":[[2019,10,25]],"date-time":"2019-10-25T11:05:18Z","timestamp":1572001518000},"page":"654","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Use of Cardiac Biomarkers for Monitoring Improvement of Left Ventricular Function by Immunoadsorption Treatment in Dilated Cardiomyopathy"],"prefix":"10.3390","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5777-2998","authenticated-orcid":false,"given":"Karolina","family":"Weinmann","sequence":"first","affiliation":[{"name":"Department of Internal Medicine II, University Ulm Medical Center, 89081 Ulm, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jakob","family":"Werner","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine II, University Ulm Medical Center, 89081 Ulm, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wolfgang","family":"Koenig","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine II, University Ulm Medical Center, 89081 Ulm, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wolfgang","family":"Rottbauer","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine II, University Ulm Medical Center, 89081 Ulm, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Walcher","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine II, University Ulm Medical Center, 89081 Ulm, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6423-0508","authenticated-orcid":false,"given":"Mirjam","family":"Ke\u00dfler","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine II, University Ulm Medical Center, 89081 Ulm, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2019,10,25]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1016\/S0735-1097(00)00568-4","article-title":"Hemodynamic effects of immunoadsorption and subsequent immunoglobulin substitution in dilated cardiomyopathy: Three-month results from a randomized study","volume":"35","author":"Felix","year":"2000","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"712-e1","DOI":"10.1016\/j.ahj.2006.06.027","article-title":"Immunoadsorption in dilated cardiomyopathy: 6-month results from a randomized study","volume":"152","author":"Staudt","year":"2006","journal-title":"Am. Heart J."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1111\/j.1365-2362.2010.02314.x","article-title":"Immunoadsorption in dilated cardiomyopathy: Long-term reduction of cardiodepressant antibodies","volume":"40","author":"Trimpert","year":"2010","journal-title":"Eur. J. Clin. Investig."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.ijcard.2004.03.001","article-title":"Immunoadsorption in idiopathic dilated cardiomyopathy, a 3-year follow-up","volume":"97","author":"Wallukat","year":"2004","journal-title":"Int. J. Cardiol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1002\/jca.21446","article-title":"Immunoadsorption therapy for dilated cardiomyopathy using tryptophan column\u2014A prospective, multicenter, randomized, within-patient and parallel-group comparative study to evaluate efficacy and safety","volume":"31","author":"Yoshikawa","year":"2016","journal-title":"J. Clin. Apheresis."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1161\/01.CIR.101.4.385","article-title":"Immunoglobulin adsorption in patients with idiopathic dilated cardiomyopathy","volume":"101","author":"Wallukat","year":"2000","journal-title":"Circulation"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/0167-5273(96)02598-3","article-title":"Removal of autoantibodies in dilated cardiomyopathy by immunoadsorption","volume":"54","author":"Wallukat","year":"1996","journal-title":"Int. J. Cardiol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.jjcc.2016.07.014","article-title":"Therapeutic effect of immunoadsorption and subsequent immunoglobulin substitution in patients with dilated cardiomyopathy: Results from the observational prospective Bad Berka Registry","volume":"69","author":"Ohlow","year":"2017","journal-title":"J. Cardiol."},{"doi-asserted-by":"crossref","unstructured":"Weinmann, K., Werner, J., Koenig, W., Rottbauer, W., Walcher, D., and Ke\u00dfler, M. (2018). Add-on Immunoadsorption Shortly-after Optimal Medical Treatment Further Significantly and Persistently Improves Cardiac Function and Symptoms in Recent-Onset Heart Failure\u2014A Single Center Experience. Biomolecules, 8.","key":"ref_9","DOI":"10.3390\/biom8040133"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.clim.2009.04.008","article-title":"Cardiac troponins and autoimmunity: Their role in the pathogenesis of myocarditis and of heart failure","volume":"134","author":"Kaya","year":"2010","journal-title":"Clin. Immunol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/j.molimm.2003.11.023","article-title":"T cell mimicry in inflammatory heart disease","volume":"40","author":"Cunningham","year":"2004","journal-title":"Mol. Immunol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1128\/CMR.19.1.80-94.2006","article-title":"Molecular mimicry, bystander activation, or viral persistence: Infections and autoimmune disease","volume":"19","author":"Fujinami","year":"2006","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"199","DOI":"10.3109\/08916930109007385","article-title":"Cardiac autoantibodies to myosin and other heart-specific autoantigens in myocarditis and dilated cardiomyopathy","volume":"34","author":"Caforio","year":"2001","journal-title":"Autoimmunity"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1161\/01.CIR.95.8.1994","article-title":"Short-term hemodynamic effects of immunoadsorption in dilated cardiomyopathy","volume":"95","author":"Felix","year":"1997","journal-title":"Circulation"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1046\/j.1526-0968.2000.00177.x","article-title":"Immunoadsorption in dilated cardiomyopathy","volume":"4","author":"Wallukat","year":"2000","journal-title":"Ther Apher."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/S0735-1097(01)01794-6","article-title":"Removal of cardiodepressant antibodies in dilated cardiomyopathy by immunoadsorption","volume":"39","author":"Felix","year":"2002","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1002\/jca.21276","article-title":"Guidelines on the use of therapeutic apheresis in clinical practice\u2014Evidence-based approach from the Writing Committee of the American Society for Apheresis: The sixth special issue","volume":"28","author":"Schwartz","year":"2013","journal-title":"J. Clin. Apheresis."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"e137","DOI":"10.1161\/CIR.0000000000000509","article-title":"2017 ACC\/AHA\/HFSA Focused Update of the 2013 ACCF\/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America","volume":"136","author":"Yancy","year":"2017","journal-title":"Circulation"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1093\/eurheartj\/ehw128","article-title":"2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC","volume":"37","author":"Ponikowski","year":"2016","journal-title":"Eur. Heart J."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1056\/NEJMra0800239","article-title":"Biomarkers in heart failure","volume":"358","author":"Braunwald","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1373\/clinchem.2011.165720","article-title":"Emerging biomarkers in heart failure","volume":"58","author":"Januzzi","year":"2012","journal-title":"Clin. Chem."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"e1054","DOI":"10.1161\/CIR.0000000000000490","article-title":"Role of biomarkers for the prevention, assessment, and management of heart failure: A scientific statement from the American Heart Association","volume":"135","author":"Chow","year":"2017","journal-title":"Circulation"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"e147","DOI":"10.1016\/j.jacc.2013.05.019","article-title":"2013 ACCF\/AHA guideline for the management of heart failure: A report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines","volume":"62","author":"Yancy","year":"2013","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1001\/jama.2017.10565","article-title":"Effect of natriuretic peptide\u2013guided therapy on hospitalization or cardiovascular mortality in high-risk patients with heart failure and reduced ejection fraction: A randomized clinical trial","volume":"318","author":"Felker","year":"2017","journal-title":"JAMA"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1161\/CIRCULATIONAHA.117.029882","article-title":"NT-proBNP (N-terminal pro-B-type natriuretic peptide)-guided therapy in acute decompensated heart failure: PRIMA II randomized controlled trial (Can NT-ProBNP-guided therapy during hospital admission for acute decompensated heart failure reduce mortality and readmissions?)","volume":"137","author":"Stienen","year":"2018","journal-title":"Circulation"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.cardfail.2017.02.001","article-title":"N-Terminal Pro\u2013B-Type Natriuretic Peptide\u2013Guided Therapy in Chronic Heart Failure Reduces Repeated Hospitalizations\u2014Results From TIME-CHF","volume":"23","author":"Davarzani","year":"2017","journal-title":"J. Card. Fail."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1016\/j.jacc.2011.03.072","article-title":"Use of amino-terminal pro\u2013B-type natriuretic peptide to guide outpatient therapy of patients with chronic left ventricular systolic dysfunction","volume":"58","author":"Januzzi","year":"2011","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1172\/JCI30634","article-title":"IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system","volume":"117","author":"Sanada","year":"2007","journal-title":"J. Clin. Investig."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1016\/j.jacc.2018.08.2165","article-title":"sST2 Predicts Outcome in Chronic Heart Failure Beyond NT\u2212proBNP and High-Sensitivity Troponin T","volume":"72","author":"Emdin","year":"2018","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/j.cardfail.2013.11.003","article-title":"Heart failure therapy\u2013induced early ST2 changes may offer long-term therapy guidance","volume":"19","author":"Breidthardt","year":"2013","journal-title":"J. Card. Fail."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/j.cardfail.2008.06.415","article-title":"Serial sampling of ST2 predicts 90-day mortality following destabilized heart failure","volume":"14","author":"Boisot","year":"2008","journal-title":"J. Card. Fail."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1159\/000338800","article-title":"Serial monitoring of soluble interleukin family member ST2 in patients with acutely decompensated heart failure","volume":"122","author":"Januzzi","year":"2012","journal-title":"Cardiology"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2378","DOI":"10.1016\/j.jacc.2017.09.026","article-title":"Prognostic value of serial ST2 measurements in patients with acute heart failure","volume":"70","author":"Baart","year":"2017","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/j.ahj.2010.06.033","article-title":"Association of ST2 levels with cardiac structure and function and mortality in outpatients","volume":"160","author":"Daniels","year":"2010","journal-title":"Am. Heart J."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.jchf.2016.09.010","article-title":"Prognostic value of soluble suppression of tumorigenicity-2 in chronic heart failure: A meta-analysis","volume":"5","author":"Aimo","year":"2017","journal-title":"JACC Heart Fail."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1161\/CIRCHEARTFAILURE.113.000207","article-title":"Soluble ST2 in ambulatory patients with heart failure: Association with functional capacity and long-term outcomes","volume":"6","author":"Felker","year":"2013","journal-title":"Circ. Heart Fail."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1093\/eurheartj\/17.suppl_F.3","article-title":"Troponin T: A diagnostic marker for myocardial infarction and minor cardiac cell damage","volume":"17","author":"Rottbauer","year":"1996","journal-title":"Eur. Heart J."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1161\/CIRCULATIONAHA.117.031560","article-title":"Prognostic value of high-sensitivity troponin T in chronic heart failure: An individual patient data meta-analysis","volume":"137","author":"Aimo","year":"2018","journal-title":"Circulation"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1007\/s12265-015-9618-4","article-title":"Concentrations of highly sensitive cardiac troponin-I predict poor cardiovascular outcomes and adverse remodeling in chronic heart failure","volume":"8","author":"Motiwala","year":"2015","journal-title":"J. Cardiovasc. Transl. Res."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1007\/s11560-013-0843-z","article-title":"Plasmapherese und Immunadsorption","volume":"9","author":"Renders","year":"2014","journal-title":"Nephrol"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1002\/ejhf.1461","article-title":"Heart failure in cardiomyopathies: A position paper from the Heart Failure Association of the European Society of Cardiology","volume":"21","author":"Polovina","year":"2019","journal-title":"Eur. J. Heart Fail."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1016\/j.ehj.2003.07.005","article-title":"N-terminal pro-brain natriuretic peptide: A new gold standard in predicting mortality in patients with advanced heart failure","volume":"24","author":"Gardner","year":"2003","journal-title":"Eur. Heart J."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1161\/CIRCHEARTFAILURE.110.958223","article-title":"High-sensitivity ST2 for prediction of adverse outcomes in chronic heart failure","volume":"4","author":"Ky","year":"2011","journal-title":"Circ. Heart Fail."}],"container-title":["Biomolecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2218-273X\/9\/11\/654\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T13:29:26Z","timestamp":1760189366000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2218-273X\/9\/11\/654"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,25]]},"references-count":43,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2019,11]]}},"alternative-id":["biom9110654"],"URL":"https:\/\/doi.org\/10.3390\/biom9110654","relation":{},"ISSN":["2218-273X"],"issn-type":[{"type":"electronic","value":"2218-273X"}],"subject":[],"published":{"date-parts":[[2019,10,25]]}}}